Who Pays My Doctor?

Healthcare provider profile · identity verified

Bob Geng, M.D.

Allopathic & Osteopathic Physicians|Internal Medicine · SAN DIEGO, CA · NPI 1356570758

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Bob Geng, M.D. received $760,491.09 in general payments during 2025 across 689 reported records.

GENZYME CORPORATION accounted for 18.9% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 49 associated products.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$760,491.09

689 reported records · 41 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
GENZYME CORPORATION Unresolved — no canonical attribution shown $143,574.2718.9%932025
GlaxoSmithKline, LLC. Unresolved — no canonical attribution shown $134,048.9017.6%952025
Regeneron Healthcare Solutions, Inc. Unresolved — no canonical attribution shown $92,046.1212.1%892025
Lilly USA, LLC Unresolved — no canonical attribution shown $77,651.8510.2%722025
Incyte Corporation Unresolved — no canonical attribution shown $50,400.926.6%492025
Eli Lilly and Company Unresolved — no canonical attribution shown $35,890.144.7%372025
Takeda Pharmaceuticals U.S.A., Inc. Unresolved — no canonical attribution shown $30,442.874.0%232025
Grifols USA, LLC Unresolved — no canonical attribution shown $24,856.153.3%242025
Novartis Pharmaceuticals Corporation Unresolved — no canonical attribution shown $21,552.392.8%282025
Amgen Inc. Unresolved — no canonical attribution shown $20,835.592.7%162025
Insmed, Inc. Unresolved — no canonical attribution shown $19,803.662.6%122025
LEO Pharma Inc. Unresolved — no canonical attribution shown $19,058.442.5%152025
Ionis Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $16,488.882.2%212025
ADMA BioManufacturing LLC Unresolved — no canonical attribution shown $12,849.271.7%222025
PFIZER INC. Unresolved — no canonical attribution shown $12,131.791.6%122025
Arcutis Biotherapeutics, Inc. Unresolved — no canonical attribution shown $9,932.081.3%62025
ABBVIE INC. Unresolved — no canonical attribution shown $8,685.831.1%62025
GC Biopharma USA, Inc. Unresolved — no canonical attribution shown $7,299.851.0%42025
SANOFI-AVENTIS U.S. LLC Unresolved — no canonical attribution shown $7,262.080.9%52025
Koru Medical Systems, Inc. Unresolved — no canonical attribution shown $6,232.000.8%12025
SANOFI US SERVICES INC. Unresolved — no canonical attribution shown $3,000.000.4%12025
Grifols Shared Services North America, Inc. Unresolved — no canonical attribution shown $2,832.690.4%32025
Regeneron Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $697.550.1%82025
KYOWA KIRIN, INC. Unresolved — no canonical attribution shown $457.270.1%62025
AstraZeneca Pharmaceuticals LP Unresolved — no canonical attribution shown $432.480.1%72025
Galderma Laboratories, L.P. Unresolved — no canonical attribution shown $310.100.0%62025
CSL Behring Unresolved — no canonical attribution shown $296.490.0%42025
Pharming Healthcare, Inc. Unresolved — no canonical attribution shown $198.980.0%32025
ARS Pharmaceuticals Operations, Inc. Unresolved — no canonical attribution shown $186.970.0%32025
Boehringer Ingelheim Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $150.000.0%12025
Kedrion Biopharma, Inc. Unresolved — no canonical attribution shown $135.440.0%12025
Greer Laboratories, Inc. Unresolved — no canonical attribution shown $123.710.0%12025
UCB, Inc. Unresolved — no canonical attribution shown $116.050.0%12025
ALK-Abello, Inc Unresolved — no canonical attribution shown $99.420.0%12025
Octapharma USA, Inc. Unresolved — no canonical attribution shown $90.720.0%22025
Organon LLC Unresolved — no canonical attribution shown $85.360.0%22025
BioCryst Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $77.390.0%12025
BioCryst US Sales Co., LLC Unresolved — no canonical attribution shown $70.680.0%52025
Aero US Inc Unresolved — no canonical attribution shown $52.870.0%12025
Cycle Pharmaceuticals Inc Unresolved — no canonical attribution shown $19.110.0%12025
Azurity Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $14.730.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$482,351.31146
Travel and Lodging$129,390.04219
Consulting Fee$121,256.2434
Food and Beverage$19,456.81286
Honoraria$8,000.002
Education$36.692

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
DUPIXENT
Normalized: dupixent		 Biological GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., Regeneron Pharmaceuticals, Inc., SANOFI-AVENTIS U.S. LLC $195,684.00 154 2025
Source payment records
NUCALA
Normalized: nucala		 Biological GlaxoSmithKline, LLC. $134,048.90 95 2025
Source payment records
EBGLYSS
Normalized: ebglyss		 Drug Eli Lilly and Company, Lilly USA, LLC $103,259.20 74 2025
Source payment records
OPZELURA
Normalized: opzelura		 Drug Incyte Corporation $50,230.90 46 2025
Source payment records
TAKHZYRO
Normalized: takhzyro		 Biological Takeda Pharmaceuticals U.S.A., Inc. $28,154.58 16 2025
Source payment records
Xembify
Normalized: xembify		 Biological Grifols Shared Services North America, Inc., Grifols USA, LLC $27,688.84 27 2025
Source payment records
DAWNZERA
Normalized: dawnzera		 Drug Ionis Pharmaceuticals, Inc. $16,336.98 19 2025
Source payment records
ACTIMMUNE
Normalized: actimmune		 Biological Amgen Inc. $12,834.91 11 2025
Source payment records
CIBINQO
Normalized: cibinqo		 Drug PFIZER INC. $12,110.83 11 2025
Source payment records
ANZUPGO
Normalized: anzupgo		 Drug LEO Pharma Inc. $11,590.22 6 2025
Source payment records
Zoryve
Normalized: zoryve		 Drug Arcutis Biotherapeutics, Inc. $9,932.08 6 2025
Source payment records
RINVOQ
Normalized: rinvoq		 Biological ABBVIE INC. $8,685.83 6 2025
Source payment records
ALYGLO
Normalized: alyglo		 Drug GC Biopharma USA, Inc. $7,299.85 4 2025
Source payment records
ADBRY
Normalized: adbry		 Biological LEO Pharma Inc. $7,195.00 7 2025
Source payment records
CUVITRU
Normalized: cuvitru		 Biological Takeda Pharmaceuticals U.S.A., Inc. $2,234.09 4 2025
Source payment records
Rhapsido
Normalized: rhapsido		 Drug Novartis Pharmaceuticals Corporation $1,033.39 5 2025
Source payment records
NEMLUVIO
Normalized: nemluvio		 Drug Galderma Laboratories, L.P. $310.10 6 2025
Source payment records
Hizentra
Normalized: hizentra		 Biological CSL Behring $296.49 4 2025
Source payment records
Arikayce
Normalized: arikayce		 Drug Insmed, Inc. $286.28 7 2025
Source payment records
AYVAKIT
Normalized: ayvakit		 Biological GENZYME CORPORATION $240.30 3 2025
Source payment records
RUCONEST
Normalized: ruconest		 Biological Pharming Healthcare, Inc. $198.98 3 2025
Source payment records
NEFFY
Normalized: neffy		 Drug ARS Pharmaceuticals Operations, Inc. $186.97 3 2025
Source payment records
WAYRILZ
Normalized: wayrilz		 Drug GENZYME CORPORATION $163.82 3 2025
Source payment records
TEZSPIRE
Normalized: tezspire		 Biological Amgen Inc. $146.68 3 2025
Source payment records
Albuked
Normalized: albuked		 Biological Kedrion Biopharma, Inc. $135.44 1 2025
Source payment records
GAMMAKED
Normalized: gammaked		 Biological Kedrion Biopharma, Inc. $135.44 1 2025
Source payment records
KEDRAB
Normalized: kedrab		 Biological Kedrion Biopharma, Inc. $135.44 1 2025
Source payment records
KOATE
Normalized: koate		 Biological Kedrion Biopharma, Inc. $135.44 1 2025
Source payment records
RhoGAM Ultra-Filtered PLUS
Normalized: rhogam ultra filtered plus		 Biological Kedrion Biopharma, Inc. $135.44 1 2025
Source payment records
ORALAIR
Normalized: oralair		 Biological Greer Laboratories, Inc. $123.71 1 2025
Source payment records
Andembry
Normalized: andembry		 Biological CSL Behring $120.80 1 2025
Source payment records
DONIDALORSEN
Normalized: donidalorsen		 Drug Ionis Pharmaceuticals, Inc. $116.73 1 2025
Source payment records
Bimzelx
Normalized: bimzelx		 Biological UCB, Inc. $116.05 1 2025
Source payment records
ORLADEYO
Normalized: orladeyo		 Drug BioCryst Pharmaceuticals, Inc., BioCryst US Sales Co., LLC $112.05 5 2025
Source payment records
TALTZ
Normalized: taltz		 Drug Lilly USA, LLC $102.59 2 2025
Source payment records
PANZYGA
Normalized: panzyga		 Biological Octapharma USA, Inc., PFIZER INC. $92.78 2 2025
Source payment records
VTAMA
Normalized: vtama		 Drug Organon LLC $85.36 2 2025
Source payment records
FASENRA
Normalized: fasenra		 Biological AstraZeneca Pharmaceuticals LP $64.70 2 2025
Source payment records
AEROGEN SOLO NEBULIZER SYSTEM
Normalized: aerogen solo nebulizer system		 Device Aero US Inc $52.87 1 2025
Source payment records
AEROGEN USB CONTROLLER SYSTEM
Normalized: aerogen usb controller system		 Device Aero US Inc $52.87 1 2025
Source payment records
Aerogen Solo; Aerogen Ultra
Normalized: aerogen solo aerogen ultra		 Device Aero US Inc $52.87 1 2025
Source payment records
CUTAQUIG
Normalized: cutaquig		 Biological Octapharma USA, Inc., PFIZER INC. $39.86 2 2025
Source payment records
XOLAIR
Normalized: xolair		 Drug Novartis Pharmaceuticals Corporation $31.54 1 2025
Source payment records
AIRSUPRA
Normalized: airsupra		 Drug AstraZeneca Pharmaceuticals LP $20.67 1 2025
Source payment records
EOHILIA
Normalized: eohilia		 Drug Takeda Pharmaceuticals U.S.A., Inc. $19.19 1 2025
Source payment records
Sajazir
Normalized: sajazir		 Drug Cycle Pharmaceuticals Inc $19.11 1 2025
Source payment records
ALVESCO
Normalized: alvesco		 Drug Azurity Pharmaceuticals, Inc. $14.73 1 2025
Source payment records
HYQVIA
Normalized: hyqvia		 Biological Takeda Pharmaceuticals U.S.A., Inc. $3.28 1 2025
Source payment records
Brinsupri
Normalized: brinsupri		 Drug Insmed, Inc. $2.97 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
GlaxoSmithKline, LLC.
Exact reporting entity; no affiliate inference		 2025 TRELEGY ELLIPTA
open payments reported associated product		 CMS Open Payments — General Payments
131532 supporting records · 37148 recipient NPIs · example record 1190332369 		Trelegy Ellipta · 2024
Exact normalized brand match · 1 Part D row		 18 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18suppressed
Dupixent SyringeDupilumab13suppressed
Montelukast SodiumMontelukast Sodium13suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $760,491.09 · 689 records GENZYME CORPORATION ACTIMMUNE, ADBRY, AEROGEN SOLO NEBULIZER SYSTEM, AEROGEN USB CONTROLLER SYSTEM, AIRSUPRA, ALVESCO, ALYGLO, ANZUPGO, AYVAKIT, Aerogen Solo; Aerogen Ultra, Albuked, Andembry, Arikayce, Bimzelx, Brinsupri, CIBINQO, CUTAQUIG, CUVITRU, DAWNZERA, DONIDALORSEN, DUPIXENT, EBGLYSS, EOHILIA, FASENRA, GAMMAKED, HYQVIA, Hizentra, KEDRAB, KOATE, NEFFY, NEMLUVIO, NUCALA, OPZELURA, ORALAIR, ORLADEYO, PANZYGA, RINVOQ, RUCONEST, Rhapsido, RhoGAM Ultra-Filtered PLUS, Sajazir, TAKHZYRO, TALTZ, TEZSPIRE, VTAMA, WAYRILZ, XOLAIR, Xembify, Zoryve 1 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error